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Introduction
The I148M variant in patatin-like phospholipase domain–containing protein 3 (PNPLA3) is found 
worldwide in 30%–50% of  all subjects (1). It increases intrahepatocellular triglycerides (IHTGs) and 
risks of  nonalcoholic steatohepatitis (NASH), alcoholic and nonalcoholic cirrhosis, and hepatocel-
lular carcinoma (2). Unlike in nonalcoholic fatty liver disease (NAFLD) associated with obesity and 
metabolic syndrome, carriers with NAFLD due to the I148M gene variant are neither insulin resis-
tant nor predisposed to develop metabolic sequelae, such as cardiovascular disease, compared with 
noncarriers (1). Indeed, several studies have recently shown the gene variant to be protective against 
cardiovascular disease (3, 4).
In humans, hepatic TGs are markedly enriched in polyunsaturated fatty acids (PUFA) in carriers 
of  the PNPLA3-I148M variant compared with noncarriers (5). This lipidome differs from the NAFLD 
lipidome associated with insulin resistance, in which liver is enriched in predominantly saturated or 
The common patatin-like phospholipase domain–containing protein 3 (PNPLA3) variant I148M 
predisposes to nonalcoholic liver disease but not its metabolic sequelae. We compared the handling 
of labeled polyunsaturated fatty acids (PUFAs) and saturated fatty acids (SFA) in vivo in humans 
and in cells harboring different PNPLA3 genotypes. In 148M homozygous individuals, triglycerides 
(TGs) in very low–density lipoproteins (VLDL) were depleted of PUFAs both under fasting and 
postprandial conditions compared with 148I homozygotes, and the PUFA/SFA ratio in VLDL-TGs was 
lower relative to the chylomicron precursor pool. In human PNPLA3-148M and PNPLA3-KO cells, 
PUFA but not SFA incorporation into TGs was increased at the expense of phosphatidylcholines, 
and under lipolytic conditions, PUFA-containing diacylglycerols (DAGs) accumulated compared 
with PNPLA3-148I cells. Polyunsaturated TGs were increased, while phosphatidylcholines (PCs) 
were decreased in the human liver in 148M homozygous individuals as compared with 148I 
homozygotes. We conclude that human PNPLA3-I148M is a loss-of-function allele that remodels 
liver TGs in a polyunsaturated direction by impairing hydrolysis/transacylation of PUFAs from DAGs 
to feed phosphatidylcholine synthesis.
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monounsaturated TGs (5). The human lipidomic data of  NAFLD in PNPLA3 variant carriers closely 
resemble the hepatic lipidomic profile of  PNPLA3-KO mice (6, 7). In the latter study, PNPLA3 was 
proposed to act as a transacylase transferring PUFAs from TG to lysophospholipids or as a TG hydro-
lase hydrolyzing PUFAs from TGs in a remodeling pathway for lipid droplet phospholipids (7).
However, data from mouse models are not easy to reconcile with the human data. PNPLA3-KO 
mice accumulate polyunsaturated TGs but do not develop hepatic steatosis (6–8). Opposite to humans 
and knock-in (KI) mice expressing a catalytically inactive PNPLA3 (PNPLA3-S47A–KI), PUFAs are 
depleted in hepatic TGs in I148M-KI mice — i.e. in mice in which the I148M has been introduced to 
the endogenous mouse PNPLA3 gene (7). Mouse PNPLA3 is approximately 68% homologous with 
human PNPLA3 (9). This difference could contribute to the discrepant results in mice as compared 
with humans. Regarding cell models, hepatic cell lines such as HuH7 and HepG2 are not ideal for 
studying the function of  the PNPLA3-I148M variant, as both cell lines are homozygous for the variant 
allele (10, 11). There are no studies addressing the function of  the PNPLA3-I148M variant in humans 
in vivo or in vitro in human cells that do not endogenously express the I148M variant and in which the 
variant has been knocked in rather than overexpressed.
In the present study, we wished to determine why PUFAs are enriched in TGs in the human liv-
er. This is important for understanding the pathogenesis of  the most important genetic risk factor of  
NAFLD. To this end, we compared the hepatic handling of  labeled PUFAs (13C-18:2) and saturated 
fatty acids (SFAs, 13C-16:0) and the composition of  very low–density lipoproteins (VLDL) in homozy-
gous carriers and noncarriers of  the PNPLA3-I148M variant. Furthermore, by using CRISPR-Cas9, we 
engineered human cells homozygous for the PNPLA3 148I allele (PNPLA3-148I, WT) to generate cell 
lines with a homozygous I148M substitution (PNPLA3-148M–KI) or a homozygous PNPLA3 deletion 
(PNPLA3-KO). In these cells, we employed “click” chemistry of  alkyne-labeled C-18:2 and C-16:0 FAs 
to analyze rapid FA fluxes during lipogenesis and lipolysis. Finally, we compared the lipid composition 
of  human liver biopsies between homozygous carriers and noncarriers of  the I148M variant.
Results
Increased IHTGs in homozygous 148M variant allele carriers (PNPLA3148MM) compared with noncarriers (PNPLA3148II). 
Characteristics of  the PNPLA3148II and PNPLA3148MM groups are shown in Table 1. The PNPLA3148MM 
group had a significantly, 3.5-fold higher IHTG content than the PNPLA3148II group (6.3% [interquartile 
range (IQR) 4.5%–14.6%] vs. 1.8% [1.0%–6.7%]) (Table 1). The PNPLA3148II and PNPLA3148MM groups 
were similar with respect to age, sex, glucose, insulin concentrations, and BMI (Table 1). There were no 
Table 1. Clinical characteristics of the subjects
PNPLA3148II PNPLA3148MM
Group size (n) 14 12
Age (years) 52.4 ± 1.8 53.1 ± 2.2
Sex (% women/men) 79/21 83/17
BMI (kg/m2) 31.8 ± 1.5 31.8 ± 2.0
Waist circumference (cm) 99.0 (92.8–109.5) 98.0 (89.1–114.3)
fP-glucose (mmol/l) 5.7 (5.3–6.0) 6.0 (5.5 –6.2)
fS-insulin (mU/l) 6.2 (3.4–9.1) 6.0 (4.4–11.7)
fP-triglycerides (mmol/l) 0.9 (0.8–1.1) 0.9 (0.6–1.4)
fP-HDL cholesterol (mmol/l) 1.49 ± 0.08 1.58 ± 0.16
fP-LDL cholesterol (mmol/l) 3.3 ± 0.2 3.4 ± 0.2
P-AST (IU/l) 25 (20–31) 27 (24–30)
P-ALT (IU/l) 21 (16–35) 24 (19–33)
P-GGT (U/l) 17 (13–48) 24 (21–35)
P-Albumin (g/l) 36.6 ± 0.6 35.7 ± 0.7
IHTG (1H-MRS, %) 1.8 (1.0–6.7) 6.3 (4.5–14.6)A
Data are in n, %, means ± SEM or median (25th–75th percentile), and statistical tests are 2-tailed Student’s t test, 
Mann-Whitney U test, and Pearson χ2 test, as appropriate. AP ≤ 0.05 compared with the PNPLA3148II group. IHTG, 
intrahepatic triglycerides. f, fasting; P, plasma; S, serum. 
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significant differences between the groups in physical activity or dietary intake, as determined by 1-week 
accelerometer data and analysis of  3-day dietary records (Supplemental Table 1; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.127902DS1).
Deficiency of  polyunsaturated TGs in VLDL in the PNPLA3148MM as compared with the PNPLA3148II group. Total 
concentrations of  plasma TG, free fatty acids (FFA), VLDL-TG and chylomicron-TG, and glucose and 
serum insulin were similar between the PNPLA3148MM and PNPLA3148II groups in the fasting state and post-
prandially at every time point (Figure 1). Lipidomic analysis of  VLDL was performed for detailed character-
ization of  VLDL-TGs in the fasting state and postprandially. The relationship between the number of  double 
bonds in VLDL-TGs and the ratio of  the mean absolute concentrations of  corresponding VLDL-TGs in 
the PNPLA3148MM as compared with the PNPLA3148II group are shown in Figure 2. The number of  double 
bonds was inversely related to the ratios of  VLDL-TGs in PNPLA3148MM vs. PNPLA3148II in the fasting state 
and at 120 minutes, 300 minutes, and 420 minutes postprandially (Figure 2). Thus, although total concentra-
tions of  VLDL-TGs were similar (Figure 1), the TGs secreted from the liver in VLDL before and during the 
meal were deficient in polyunsaturated TGs in the PNPLA3148MM as compared with the PNPLA3148II group.
Deficiency of  PUFAs in VLDL-TG FAs in the PNPLA3148MM as compared with the PNPLA3148II group. The per-
centage of  distinct FAs of  total FAs in VLDL-TGs in the PNPLA3148MM as compared with the PNPLA3148II 
group in the fasting state are shown in Figure 3A. Saturated palmitate (16:0), monounsaturated oleate (18:1), 
and polyunsaturated linoleate (18:2) were the most abundant FAs in VLDL-TGs in both groups (Figure 3A). 
Figure 1. Similar total concentrations of circulating lipids, glucose, and insulin in the PNPLA3148MM vs. PNPLA3148II 
groups. Concentrations of (A) plasma TGs, (B) free fatty acids, (C) VLDL-TG, (D) chylomicron-TG, (E) glucose, and (F) 
serum insulin in the PNPLA3148MM and PNPLA3148II groups in the fasting state (0 minutes) and during the postprandial 
period. Data are shown as mean ± SEM. The blue lines and circles denote the PNPLA3148II (n = 14) group, and the red 
lines and squares denote the PNPLA3148MM (n = 12) group. There were no significant differences between the groups as 
determined using 2-way ANOVA.
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The percentage of  18:2 FA in VLDL-TG FAs was significantly lower in the PNPLA3148MM as compared 
with the PNPLA3148II group in the fasting state (Figure 3A) and during the entire postprandial period (Fig-
ure 3, B and C). In contrast, the percentage of  SFA 16:0 in VLDL-TG FAs was significantly higher in the 
PNPLA3148MM as compared with the PNPLA3148II group in the fasting state (Figure 3A) and during the post-
prandial period (Figure 3, B and D).
The relationship between the number of  double bonds in VLDL-TG FAs and the ratio of  the mean 
absolute concentrations of  corresponding VLDL-TG FAs in the PNPLA3148MM as compared with the 
PNPLA3148II group are shown in Figure 3E. The number of  double bonds was inversely related to the ratios 
of  VLDL-TG FAs in homozygous carriers vs. noncarriers during the postprandial period (Figure 3E). 
These data show that there is PUFA deficiency in VLDL-TG in 148M carriers and support the hypothesis 
that PUFAs are retained in the liver in PNPLA3148MM as compared with the PNPLA3148II group.
In vivo evidence of  retention of  labeled 13C-18:2 PUFAs in the human liver in PNPLA3148MM compared with 
PNPLA3148II group. Dietary FAs are transported from the intestinal lumen to the circulation in chylomi-
cron-TGs, which then undergo hydrolysis and are taken up by the liver (12). VLDL-TGs are produced 
exclusively by the liver (12). Thus, to compare handling of  PUFAs and SFAs in the liver, we calculat-
ed their ratio in VLDL-TGs and chylomicron-TGs. The PNPLA3148MM group had a significantly lower 
13C-18:2/13C-16:0 ratio in VLDL-TGs compared with the PNPLA3148II group (P < 0.01) when related 
to the corresponding ratio in the chylomicron precursor pool (Figure 3F). There were no differences in 
enrichment of  either of  the FAs in the chylomicron precursor pools between the PNPLA3148MM and the 
PNPLA3148II groups (Supplemental Figure 1).
Increased storage of  neutral lipids in homozygous PNPLA3-148M–KI human cells. We used human epidermoid 
carcinoma A431 cells that are readily amenable for genetic manipulation and homozygous for the PNP-
LA3-148I allele. PNPLA3 is expressed in the skin (13) and in A431 cells at levels roughly comparable with 
HepG2 cells (Human Protein Atlas; https://www.proteinatlas.org/). We have used these cells in our earlier 
studies on lipid processing and storage (14, 15). Starting from the WT PNPLA3 cells, we engineered PNP-
LA3-KO cells, as well as cells expressing the 148M allele as homozygous (PNPLA3-148M–KI), and generated 
Figure 2. Differences between distinct VLDL-TGs in the PNPLA3148MM vs. PNPLA3148II groups according to the number 
of double bonds. Panels show linear regression lines between the number of double bonds in VLDL-TGs and the log2 
fold-change of absolute concentrations of corresponding VLDL-TGs in the PNPLA3148MM (n = 12) vs. the PNPLA3148II (n = 
14) group (A) in the fasting state (0 minutes) and (B) 120 minutes, (C) 300 minutes, and (D) 420 minutes following the 
meal. Each circle denotes a distinct VLDL-TG species. Significance was determined using linear regression analysis.
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Figure 3. Differences in the composition and handling of VLDL-TG fatty acids in the PNPLA3148MM vs. the PNPLA3148II groups. (A) Percentage of distinct 
fatty acids of total unlabelled fatty acids in VLDL-TG in the PNPLA3148MM (red bars, n = 12) and PNPLA3148II (blue bars, n = 14) groups in the fasting state. 
(B) Fold change in the percentage of distinct fatty acids of total unlabeled fatty acids in VLDL-TGs in the PNPLA3148MM (n = 12) vs. the PNPLA3148II (n = 
14) groups in the fasting state (0 minutes) and during the postprandial period. The x-axis denotes distinct fatty acids, and y-axis denotes postprandial 
time. Each square represents log2 fold-change of the percentage of a distinct fatty acid of total fatty acids in VLDL-TG in the PNPLA3
148MM (n = 12) vs. the 
PNPLA3148II (n = 14) groups at that time point. (C and D) Percentage of unlabeled polyunsaturated fatty acid linoleate (18:2) (C) and saturated fatty acid 
palmitate (16:0) (D) of total fatty acids in VLDL-TG in the PNPLA3148MM (red squares and lines, n = 12) and PNPLA3148II (blue circles and lines, n = 14) groups 
in the fasting state and during the 420-minute postprandial period. (E) Linear regression lines between the number of double bonds in VLDL-TG fatty acids 
and the log2 fold-change of absolute concentrations of corresponding VLDL-TG fatty acid in the PNPLA3
148MM (n = 12) vs. the PNPLA3148II (n = 14) groups in 
the fasting state (0 min; black circles) and at 120 minutes (red squares), 180 minutes (green triangles pointing up), 240 minutes (blue triangles pointing 
down), 300 minutes (purple diamonds), 360 minutes (orange circles), and 420 minutes (turquoise squares). (F) Ratio of 13C-18:2 to 13C-16:0 fatty acids in 
plasma VLDL-TG related to the corresponding ratio in the chylomicron precursor pool in the PNPLA3148MM (red squares and lines, n = 12) and the PNPLA3148II 
(blue circles and lines, n = 14) groups. Data are shown as mean ± SEM. *P < 0.05. Significance was determined using 2-tailed Student’s t test for unpaired 
data, 2-way ANOVA, and linear regression as appropriate.
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stable cell lines. Under basal culture conditions, the PNPLA3-148M–KI cells exhibited, as expected, elevated 
neutral lipid levels (TGs and cholesteryl esters, CEs) compared with WT cells (30.67 ± 4.7 [SEM] ng lipid/μg 
protein vs. 18.27 ± 2.4 [SEM], n = 6). We also engineered cells stably expressing GFP-tagged PNPLA3-148I or 
PNPLA3-148M on a PNPLA3-KO background. In these cells, both forms of PNPLA3 are expressed at similar 
levels (Supplemental Figure 2A) and associate with lipid droplets (Supplemental Figure 2B). These results are 
in keeping with our previous findings in hepatoma cells (16).
Increased storage of  PUFAs but not SFAs in PNPLA3-148M–KI and PNPLA3-KO cells. We then studied 
how the addition of  saturated or increasingly unsaturated exogenous FAs affects lipid storage in A431 
cells. Fluorescence microscopy revealed that all 3 cell lines generated lipid droplets when exposed to 
Figure 4. Characterization of lipid storage in homozygous 
PNPLA3-148I, PNPLA3-148M, and PNPLA3-KO A431 cells. 
Cells were incubated for 24 hours in the presence of 100 μM 
palmitate, oleate, linoleate, or mixture of DHA and EPA (50 
μM each); they were fixed and stained with lipid droplet dye 
LD540. Scale bar: 10 μm. The bar graph depicts percentage 
of cell area occupied by lipid droplets ± SEM. n =  62–76 
cells. * P < 0.05 (1-way ANOVA with Dunnett’s correction).
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FAs for 24 hours. Expectedly, oleic and palmitic acid were potent inducers of  lipid droplets, and PUFAs 
were less efficient (Figure 4). However, lipid droplet accumulation induced by PUFAs was strikingly 
increased in PNPLA3-148M–KI and PNPLA3-KO cells. This effect was not observed with saturated or 
monounsaturated FA. These results show that lack of  PNPLA3 activity results in preferential seques-
tering of  PUFAs to neutral lipids.
Increased incorporation of  PUFAs to TGs and decreased incorporation to PCs in PNPLA3-148M–KI and PNP-
LA3-KO cells. Click chemistry is powerful for tracing rapid FA metabolism (15, 17). Using this approach, 
we compared how alkyne-palmitate and alkyne-linoleate are metabolized into major cellular lipid species 
during 15 minutes of  labeling. The partitioning of  alkyne-palmitate to phosphatidylcholines (PCs), diacyl-
glycerols (DAGs) and TGs was similar between PNPLA3 genotypes (Figure 5A). At this time point, the 
majority of  alkyne-linoleate was found in PCs in all cell lines (Figure 5B). However, in PNPLA3-148M–
KI and PNPLA3-KO cells, the fraction of  alkyne-linoleate in PC was significantly reduced and, in TGs, 
concomitantly increased as compared with WT (Figure 5B). Moreover, the percentage of  FFA was higher 
Figure 5. Partitioning of alkyne-labeled fatty acid in homozygous PNPLA3-148I, PNPLA3-148M, and PNPLA3-KO 
A431 cells. (A) Cells were incubated for 15 minutes with 100 μM alkyne-palmitate and then extracted, click-reacted, 
and analyzed by TLC. Bars represent percentage of incorporated alkyne-palmitate in indicated lipid species ± SEM. n 
= 9 from 3 individual experiments. (B) Cells were incubated for 15 minutes with 100 μM alkyne-linoleate and analyzed 
as in A. Bars represent percentage of incorporated alkyne-linoleate in indicated lipid species ± SEM. n = 9–17 from 
4–6 individual experiments; * P < 0.05 (1-way ANOVA with Dunnett’s correction). (C) Cells were incubated for a 1-hour 
minimum with 100 μM alkyne-linoleate in the presence of cholesterol esterification inhibitor. After labeling, cells were 
either collected (0 minutes chase) or further incubated in lipoprotein-deficient medium supplemented with cholesterol 
esterification and DGAT inhibitors for 15, 30, or 60 minutes; they were then analyzed as in A. Bars represent percentage 
of incorporated alkyne-linoleate in indicated lipid species, normalized to PNPLA3-148I cells at 0 minutes chase ± SEM. 
n = 5–8 from 3–4 individual experiments; *P < 0.05 (1-way ANOVA with Dunnett’s correction).
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in PNPLA3-148M–KI and PNPLA3-KO cells (29.6% ± 2.4% and 29.1% ± 2.5% respectively, n = 9) com-
pared with WT cells (21.3% ± 3.7%, n = 9), implying defects in incorporation of  PUFAs into PC.
Accumulation of  DAGs in PNPLA3-148M–KI and PNPLA3-KO cells in lipolytic conditions. Due to the 
observed differences between PNPLA3 genotypes in PUFA metabolism and the reported PNPLA3 lipase 
activity (18, 19), we next measured release of  linoleic acid from TG stores. To this end, we incubated WT 
A431 cells with alkyne-linoleate for 1 hour in the presence of  a cholesterol esterification inhibitor (PKF-
035) to ensure maximal neutral lipid deposition as TGs. The cells were then either immediately harvested 
(0 minutes chase) or incubated for 15, 30, or 60 minutes (chase) in the presence of  diacylglycerol O-acyl-
transferase 1 (DGAT-1) and -2 inhibitors that prevent TG synthesis as well as a cholesterol esterification 
inhibitor. As the inhibitors prevent FA reesterification to neutral lipids, under these conditions, cells start to 
hydrolyze the generated TGs. As expected, alkyne-linoleate containing TGs and DAGs decreased during 
chase, and this was paralleled by increased partitioning of  alkyne-linoleate into phospholipids, with mar-
ginal levels of  FFAs (Supplemental Figure 3A).
When the effect of  PNPLA3 genotype on TG hydrolysis was investigated, we found that both PNP-
LA3-148M–KI and PNPLA3-KO cells had elevated TG levels at the end of  alkyne-linoleate labeling as 
compared with PNPLA3-148I (Figure 5C). The increase in TGs in PNPLA3-KO and PNPLA3-148M–KI 
cells is consistent with the idea that the human gene variant increases TGs because it acts as a loss-of-
function variant. During the 1-hour chase, TGs started to diminish but stayed elevated in both genotypes 
relative to PNPLA3-148I cells (Figure 5C). Of  note, although TGs stayed elevated in PNPLA3-KO and 
PNPLA3-148M–KI cells compared with WT PNPLA3-148I cells, we did not observe major differences in 
the hydrolysis rate of  TGs under lipolytic conditions between these cells. This does not favor the idea that 
PNPLA3 functions mainly in TG hydrolysis.
Strikingly, under lipolytic conditions, we observed a pronounced increase in DAGs in both PNP-
LA3-148M–KI and PNPLA3-KO cells as compared with WT (Figure 5C). This effect was not observed 
during the 15-minute labeling (Figure 5B), suggesting that the increase was not due to increased generation 
of  DAGs but rather to their impaired hydrolysis. In PNPLA3-148M–KI and PNPLA3-KO cells, there was 
also a tendency for decreased incorporation of  alkyne-linoleate into PCs, but the difference was not signifi-
cant (Supplemental Figure 3B). This is not surprising because, during the course of  hours, linoleic acid can 
end up in the PC pool via several pathways.
Polyunsaturated TGs are enriched while PCs are deficient in the human liver in homozygous carriers of  the PNP-
LA3-I148M variant compared with noncarriers. Since polyunsaturated TGs accumulated in the PNPLA3-148M-
KI cells at the expense of  PCs, we next asked whether the enrichment of  polyunsaturated TGs would be 
associated with a decrease in PCs in the human liver in homozygous carriers of  the PNPLA3-I148M variant 
Figure 6. Polyunsaturated TGs are enriched, while PCs are deficient in the human liver in homozygous carriers 
(PNPLA3148MM) as compared with noncarriers (PNPLA3148II) of the PNPLA3-I148M variant. The x-axis denotes log2 
fold-change in hepatic concentration of a given lipid in PNPLA3148MM (n = 7) as compared with PNPLA3148II (n = 64) group. 
The y-axis denotes negative logarithm of P value of 2-tailed Student’s t test comparing hepatic concentrations of a 
given lipid in PNPLA3148MM as compared with PNPLA3148II group. Red squares denote TGs, and blue circles denote PCs. 
Horizontal dashed line represents –log10(0.05). Each symbol represents distinct hepatic lipid species. Lipid species that 
were significantly decreased in the PNPLA3148MM as compared with the PNPLA3148II group are listed on the left side of 
the figure, while those that were increased are listed on the right side in the order of significance. Data in this figure are 
from separate liver biopsy cohort described earlier (5).
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as compared with noncarriers. To this end, we reanalyzed previously described data of  human liver lipidome 
(5) in homozygous I148M variant carriers and noncarriers. As previously reported, the livers of  the I148M 
variant carriers were enriched in polyunsaturated TGs, such as TG(56:6) and TG(58:6) (P < 0.05) (Figure 6). 
Consistent with the in vitro data, the livers of  homozygous I148M variant carriers were deficient in multiple 
PCs such as PC(36:6) and PC(32:2), as compared with noncarriers (P < 0.05) (Figure 6).
Discussion
Liver TGs in human liver biopsies are markedly polyunsaturated in PNPLA3148M gene variant carriers as 
compared with noncarriers (5). The present data show, using a combination of  GC, ultra-high performance 
liquid chromatography-tandem mass spectrometry (UHPLC-MS), and stable isotope techniques, that this 
reflects increased retention of  PUFAs in the liver and results in PUFA deficiency in VLDL-TG secreted 
by the liver. The evidence from the in vivo studies can be summarized as follows. In the PNPLA3148MM as 
compared with the PNPLA3148II group both in the fasting state and postprandially, (a) the number of  dou-
ble bonds in VLDL-TGs measured by UHPLC-MS (Figure 2) and (b) the proportion of  18:2 FA (GC) in 
VLDL-TGs (Figure 3C) were lower, and (c) PUFAs in VLDL-TGs (GC) were deficient (Figure 3E). When 
the subjects ingested equal amounts of  a saturated (16:0) and a polyunsaturated (18:2) FA in a meal labeled 
with respective stable isotope tracers, the ratio of  labeled 18:2 vs. 16:0 was lower in the PNPLA3148MM than 
the PNPLA3148II group (Figure 3F). There are no previous studies comparing the composition of  VLDL-
TG either in the fasting state or postprandially between PNPLA3148MM and PNPLA3148II groups or kinetic 
studies addressing function of  the 148M variant in humans.
To explore the mechanism explaining retention of  PUFAs in the human liver, we engineered PNP-
LA3-KO cells as well as cells expressing the 148M allele as homozygous (PNPLA3-148M–KI) and generat-
ed stable cell lines. This KI model of  the PNPLA3 variant is the first to our knowledge to examine the impact 
of  endogenous levels of  the human PNPLA3 variant on lipid composition and metabolism. In previous 
studies using human cell lines (16, 20, 21), the gene variant was overexpressed, potentially causing artefacts.
Lipid droplet accumulation induced by PUFAs, but not by saturated or monounsaturated FA, was 
strikingly increased in PNPLA3-148M–KI and PNPLA3-KO cells. These results suggest that lack of  PNP-
LA3 activity results in preferential sequestering of  PUFAs to neutral lipids and that the 148M variant 
resembles loss of  PNPLA3 function in human cells.
Studies using click chemistry allow tracing of  rapid changes in FA metabolism (17). In PNP-
LA3-148M–KI and PNPLA3-KO cells, the fraction of  alkyne-linoleate in PC was significantly reduced 
and, in TGs, increased as compared with WT cells. In human liver samples, concentrations of  polyunsat-
urated PCs were significantly decreased, while TGs were increased in the livers of  homozygous carriers of  
the PNPLA3-I148M variant as compared with noncarriers (Figure 6). These data closely resemble those of  
KI mice expressing a catalytically inactive PNPLA3 variant (PNPLA3-S47A–KI mice) but oppose those 
characterizing PNPLA3-148M–KI mice (7). In these mice, very long–chain PUFAs are enriched in TGs 
and depleted in phospholipids. Therefore, the human PNPLA3-148M variant resembles human and mouse 
PNPLA3 loss of  function.
In PNPLA3-148M and PNPLA3-KO cells, PUFAs containing DAGs accumulated under lipolytic con-
ditions compared with PNPLA3-148I cells. This was paralleled by a tendency for decreased incorporation 
of  PUFAs into PCs in PNPLA3-148M and PNPLA3-KO cells. These data suggest that PNPLA3 promotes 
transfer of  PUFAs from DAGs to generate polyunsaturated PCs, thus refining the model proposed by Mit-
sche et al. (7). It is conceivable that PNPLA3 acts as a PUFA-specific transacylase, catalyzing the transfer 
of  PUFAs in DAGs generated from TG hydrolysis (such as 2,3-DAGs), to yield DAGs compatible with 
PC generation (1,2-DAGs). Alternatively, PNPLA3 may act as a PUFA-specific lipase hydrolyzing PUFAs 
from DAGs, to be used for the synthesis of  PUFA-containing PCs. Importantly, the PNPLA3-148M vari-
ant had similar effects on lipid metabolism as PNPLA3 deletion. While we cannot exclude the possibility 
that I148M substitution results in altered substrate specificity of  the enzyme, the data strongly suggest that 
the I148M substitution results in loss of  PNPLA3 activity in human cells. Either way, I148M remodels liver 
TGs in the human liver in a polyunsaturated direction (22). This lipid composition opposes the saturated 
TG composition characterizing liver in NAFLD associated with insulin resistance (metabolic NAFLD) 
(5, 23). The retention of  polyunsaturated TGs in the liver may explain why carriers of  the PNPLA3 gene 
variant are protected against cardiovascular disease, despite having an increase in liver fat content (3, 4).
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Methods
Subjects. A total of  26 subjects who were homozygous for either the C or the G allele at rs738409 and 
fulfilled the inclusion and exclusion criteria (vide infra) were recruited among nondiabetic individuals 
who had previously been genotyped for PNPLA3 at rs738409 in our laboratory (24) or in the popula-
tion-based National FINRISK 2007 (25).
Inclusion criteria included: (a) age 18–65 years; (b) PNPLA3 genotype CC or GG at rs738409; and 
(c) alcohol consumption less than 20 g per day for women and less than 30 g per day for men. Exclusion 
criteria included: (a) known acute or chronic disease other than obesity, NAFLD, or hypertension on the 
basis of  medical history, physical examination, and standard laboratory tests (complete blood count, serum 
creatinine, or electrolyte concentrations); (b) clinical or biochemical evidence of  liver disease other than 
NAFLD, or clinical signs or symptoms of  inborn errors of  metabolism; (c) history or current use of  toxins 
or drugs associated with liver steatosis; (d) history or current use of  lipid lowering medications; and (e) 
pregnancy or lactation.
Clinical study design. The study consisted of  (a) a screening visit, (b) a metabolic study visit, and (c) a visit 
to the imaging center for quantification of  IHTG using proton magnetic resonance spectroscopy (1H-MRS).
The screening visit was performed after an overnight fast. A history and physical examination were 
performed to review the inclusion and exclusion criteria. Blood samples were obtained for measurement 
of  circulating blood count, glucose, Hemoglobin A1c (HbA1c), serum insulin, thyroid-stimulating hormone, 
hepatitis C virus antibody, plasma glucose, low-density lipoprotein (LDL) cholesterol and high-density 
lipoprotein (HDL) cholesterol, TG, albumin, thromboplastin time, C-reactive protein, sodium, potassium, 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and γ 
glutamyltransferase (GGT) concentrations as described (24).
After the screening visit, the subjects wore portable accelerometers (GT3X, Actigraph) for 7 days to 
estimate their physical activity. The subjects were asked to collect a 3-day dietary record to determine 
their baseline dietary composition. The dietary records were analyzed using the AivoDiet software (version 
2.0.2.3; Aivo Finland).
Metabolic study visit. For 3 days prior to the metabolic study day, the subjects were asked to avoid foods 
naturally enriched in 13C (such as sea food, corn, and sugar), alcohol, and strenuous exercise. In the previous 
evening before the metabolic study, the subjects consumed a standardized meal (a vegetarian sandwich, 330 
kcal, 21 g fat, 25 g carbohydrate, and 9 g protein, produced by Ravioli). The subjects came to the clinical 
research center after an overnight fast. Body composition (InBody720; BioSpace), weight, height, and waist 
circumference were measured as described (5). A cannula was inserted into an antecubital vein, and baseline 
blood samples were taken to measure plasma albumin, AST, ALT, ALP, GGT, bilirubin, C-peptide, glucose, 
LDL and HDL cholesterol, and TG concentrations, as well as serum insulin concentrations. Participants 
were then fed a mixed test meal containing 44 g carbohydrate, 10 g protein, and 37 g fat, with 100 mg of  
[U-13C]palmitic acid and 100 mg of  [U-13C]linoleic acid (both from Cambridge Isotopes) added to trace the 
fate of  the dietary FAs (26). The meal consisted of  40 g Kellogg’s Rice Krispies with 200 g skimmed milk 
and a chocolate milkshake containing 20 g butter, 20 g rapeseed oil, 3 tbs sweetener, and 2.4 g cocoa powder.
Blood samples were taken at 0, 60, 120, 180, 240, 300, 360, and 420 minutes after the consumption of  
the test meal for measurement of  plasma glucose, TG, FFAs, and serum insulin concentrations, and at 0, 
120, 180, 240, 300, 360, and 420 minutes for isolation of  VLDL and chylomicrons by ultracentrifugation, as 
described (27). The FA composition and concentrations of  13C-18:2 and 13C-16:0 FAs were determined in total 
plasma, plasma FFA, and the VLDL and chylomicron fractions (vide infra). Lipidomics analyses (vide infra) 
were performed using the VLDL fraction using UHPLC-MS at the time points of  0, 120 ,and 420 minutes.
Imaging visit. Before the metabolic study visit, the subjects underwent 1H-MRS to quantify IHTG 
content (vide infra).
Isolation of  VLDL and chylomicron fractions. Separations of  chylomicron of  Svedberg flotation rate (Sf) 
>400 and VLDL-rich fraction (Sf20-400) were made by sequential flotation using density gradient ultracen-
trifugation (Beckman L-80, Beckman Coulter) as previously described (23).
FA isotopic enrichment. To determine the specific FA composition and isotopic enrichment, total lipids 
were extracted from plasma, and VLDL and chylomicrons, and FA methyl esters (FAMEs) were prepared 
(28, 29). The FA compositions (μmol/100 μmol total FA) of  these fractions were determined by gas chroma-
tography (GC), and the FA concentrations were calculated (27). [U-13C]palmitate and [U-13C]linoleate enrich-
ments were measured in plasma FFA, TG, Sf >400 (chylomicron-TG), Sf20-400–TG, and VLDL-TG FAMEs 
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derivatives using a Delta Plus XP GC-combustion isotope ratio mass spectrometer (Thermo Electron) (30). 
The tracer-to-tracee ratio (TTR) of  a baseline measurement before administration of  [U-13C]palmitate was 
subtracted from the TTR of each sample to account for natural abundance. The TTRs for [U-13C]palmitate 
and [U-13C]linoleate were multiplied by the corresponding unlabeled concentrations to give plasma and lipo-
protein tracer concentrations (26).
Lipidomic analysis of  VLDL-TG using UHPLC-MS. The UHPLC–quadrupole time of  flight mass spec-
trometer (QTOFMS) analyses were done in a similar manner as described earlier with some modifica-
tions (31). UHPLC-QTOFMS system was from Agilent Technologies, combining 1290 Infinity system 
and 6545 QTOFMS, interfaced with a dual jet stream electrospray (dual ESI) ion source. MassHunter 
B.06.01 software (Agilent Technologies) was used for all data acquisition and MZmine 2 was used for 
data processing (32). ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, particle size 1.7 μm) by 
Waters Corporation was used for the UHPLC separation. The lipidomics methods are described in detail 
in Supplemental Methods. The analyses covered most of  the main molecular lipids, including ceramides, 
dihydroceramides, TGs, DAGs, sphingomyelins, hexosylceramides, PC, phosphatidylethanolamines 
(PE), phosphatidylserines (PS), and lysoPC. The lipid identification was based on an internal library, 
which had been constructed based on accurate mass measurements in combination with tandem mass 
measurements. For specific lipids, the composition of  FA chains had been determined with separate mea-
surements, and for those, the FA composition was specified — e.g., TG(14:0/16:0/18:0).
Measurement of  IHTG content by 1H-MRS. IHTG content was measured by 1H-MRS performed on a 
clinical 1.5T Siemens Avantofit imager. MRS data was analyzed using jMRUI v5.2 software with AMARES 
algorithm as described (33).
Lipidomic analysis of  the human liver. We performed reanalysis of  TGs and PCs in homozygous carriers 
(n = 7) and noncarriers (n = 64) of  the PNPLA3-I148M variant in previously described data of  human liver 
lipidome of  a separate cohort (5). Briefly, human liver biopsies were obtained during laparoscopic surgery 
and immediately frozen in liquid nitrogen. Subsequently, molecular lipids were measured using a Q-TOF 
Premier (Waters Corporation) QTOFMS combined with an Acquity Ultra Performance LC (Waters Cor-
poration) as previously described (5).
Other analyses from human samples. The fasting plasma glucose was measured using the hexokinase 
method on an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd.). Serum insulin concentra-
tion was determined by time-resolved fluoroimmunoassay using an Insulin Kit (AUTOdelfia, Wal-
lac). HbA1c was measured with immunoturbidometric method (Abbott Laboratories) and plasma ALT, 
AST, and GGT concentrations were measured using photometric International Federation of  Clinical 
Chemistry methods (Abbott Laboratories). Plasma ALT, AST, and GGT activities were determined as 
recommended by the European Committee for Clinical Laboratory Standards, and plasma TG, total, 
LDL and HDL cholesterol concentrations were measured using enzymatic kits and an autoanalyzer 
(Roche Diagnostics Hitachi 917, Hitachi Ltd.). Plasma albumin was measured using a photometric 
method on an autoanalyzer (Modular Analytics EVO; Hitachi High-Technologies Corporation).
Cell culture and generation of  CRISPR cell lines. Human epidermoid carcinoma A431 cells (ATCC) were 
cultured in DMEM (Lonza) with 10% FBS (Thermo Fisher Scientific) containing L-glutamine (2 mM) 
(MilliporeSigma) and streptomycin/penicillin (100 U/ml each) (Lonza). PNPLA3-KO and I148M-KI cell 
lines were constructed using CRISPR/Cas9-mediated genome editing (34). Briefly, a homology-directed 
repair template was generated by PCR (primer sequences 5′ - ATACACGCGTCCAGTCCAAGGAACCT-
GTCC - 3′ and 5′ - ATACGTCGACGCAGTAAGTTTTGCTGCCCG - 3′), by using Huh7 genomic DNA 
as a template, and ligated into pGL3-Basic vector. The construct was transfected into A431 cells, together 
with a vector encoding Cas9, sgRNA targets flanking the mutation site (sense: 5′ - CACCGTAGAAGGG-
GATGAAGC - 3′; antisense: 5′ - AAACGCTTCATCCCCTTCTAC - 3′), and a puromycin selection mark-
er. Clones were isolated after transient selection with puromycin by limiting dilution. Homozygous muta-
tions were validated by genomic PCR. With this protocol, we obtained a homozygous PNPLA3-I148M–KI 
cell line, as well as a homozygous PNPLA3-KO cell line with a 2-bp deletion after 146C, resulting in a 
frameshift and premature termination of  translation (PNPLA3-KO).
Lipid analyses from cells. For the determination of  unlabeled lipids, cells were extracted and lipids analyzed 
by high-performance thin layer chromatography as in ref. 35. Click labeling and analyses were performed 
essentially as described (15, 17). Briefly, for alkyne-FA labeling, cells grown in 12-well plates were incubated 
at +37°C, 5% CO2 for 15 minutes in loading medium containing serum-free DMEM supplemented with 1% 
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FA free BSA, and 100 μM alkyne-linoleate (Cayman Chemical) or alkyne-palmitate (Avanti Polar Lipids). In 
lipolysis experiments, a cholesterol esterification inhibitor (Sandoz PKF 58-035, 2 μg/ml) was added, and the 
labeling was performed for 1 hour. For chase, cells were incubated with serum-free DMEM containing 5% 
lipoprotein-deficient serum (LPDS), prepared as described in ref. 36; PKF 58-035 (2 μg/ml); and DGAT-1 
and DGAT-2 inhibitors (5 μM each, MilliporeSigma, PZ0207 and PZ0233) for 15, 30, or 60 minutes. Lipid 
extraction, click reaction, and analysis of  alkyne FA incorporation into selected lipids (TG; 1,2/2,3-DAG; 
PE; and PC) by thin-layer chromatography was performed as in ref. 17.
Microscopy. For lipid droplet analyses, cells were incubated for 24 hours with BSA-complexed 100 μM 
palmitate, oleate, linoleate, or a mixture of  docosahexaenoic acid (DHA, 22:6[n-3]) and eicosapentaenoic 
acid (EPA, 20:5[n-3]) (50 μM each) (MilliporeSigma) for 24 hours. The cells were fixed with 4% PFA, 
stained with lipid droplet stain LD540 (37) (Princeton BioMolecular Research), and imaged with Nikon 
Eclipse Ti-E N-STORM epifluorescence microscope. Thresholded lipid droplet area as percentag of  total 
cell area was analyzed from micrographs with ImageJ FIJI (NIH).
Statistics. Continuous variables were tested for normality using the Kolmogorov-Smirnov test. The inde-
pendent 2-tailed Student’s t and Mann-Whitney U tests were used to compare normally and nonnormally 
distributed data, respectively. Normally distributed data were reported in means ± SEM, while nonnormally 
distributed were reported in medians and interquartile ranges. Pearson χ2 test was used to evaluate if  the dis-
tributions of categorical variables differ between the groups. The FA composition of VLDL-TG data was ana-
lyzed by a 2-way ANOVA. AUC for 13C-18:2/13C-16:0 FAs in chylomicron-TG and VLDL-TG were calculated 
using the trapezoid method. The former AUC was analyzed with respect to the latter AUC using linear regres-
sion. The UHPLC-MS data were analyzed by relating the ratio of a given VLDL-TG in the PNPLA3148MM vs. 
the PNPLA3148II group to the number of double bonds in that VLDL-TG using linear regression. Statistical 
analyses were performed by using IBM SPSS Statistics 23.0.0.0 version and GraphPad Prism 7.0d for Mac OS 
X (GraphPad Software). A P value of less than 0.05 indicated statistical significance. For in vitro experiments, 
statistical significance was determined by 1-way ANOVA with Dunnett’s correction in GraphPad Prism 7.0.
Study approval. The study protocols were approved by the ethics committee of  the Hospital District of  
Helsinki and Uusimaa, Helsinki, Finland. The studies were conducted in accordance with the Declara-
tion of  Helsinki. Each participant provided written informed consent after being explained the nature and 
potential risks of  the study.
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